The New England Journal of Medicine published a fascinating article about the experiences of whistleblowers who blew the whistle against pharmaceutical companies. (The article is below.) The article confirms what relator counsel have always know: almost all such whistleblowers blow the whistle for safety reasons. For example, the article reveals that a large percentage of whistleblowers reported they finally stepped forward after "the autopsy reports" showed the deadly side effects of the off-label uses of FDA-approved drugs but the company refused to fix the problem.
Here is the article:
NE Engl J Med (May 2010)